Dengue is a viral disease transmitted by mosquitoes which has spread rapidly in all WHO regions in recent years. The dengue virus is mainly transmitted by female mosquitoes from the genus Aedes aegypti and to a lesser degree, from Aedes albopictus. The diseases transmitted by these vector mosquitoes are Chikungunya, yellow fever and Zika viruses. Dengue is prevalent in the tropical geographic regions, induced by precipitation, temperature, relative humidity and unplanned rapid urbanization with local risk variability.
Acetaminophen, Dengvaxia and Qdenga are prescribed treatment options in dengue fever, with supportive care for dengue. The increasing prevalence of dengue, advent of vaccination programs, growth of medical insurance in emerging countries and increasing R&D funding are expected to drive the dengue treatment market growth. Moreover, strategic initiative by market player and technological development to detect dengue bolsters the dengue treatment market growth.
Access Full Report @ https://www.databridgemarketresearch.com/ru/reports/global-dengue-treatment-market
Data Bridge Market Research analyses that the Global Dengue Treatment Market is expected to reach USD 2,121.43 million by 2031 from USD 878.54 million in 2023, growing at a CAGR of 11.6% in the forecast period of 2024 to 2031. Rising wave of dengue vaccine launches is driving the market.
Key Findings of the Study
- Rising Wave of Dengue Vaccine Launches
The rise of dengue vaccine launches marks as an important factor in the fight against this mosquito-borne disease. With increasing awareness of the global burden of dengue and the pressing need for effective prevention strategies, pharmaceutical companies are stepping up their efforts to develop and introduce vaccines. This surge in vaccine launches serves as a significant driver for market growth, as it expands the arsenal of tools available to healthcare professionals and public health authorities. As more vaccines enter the market, competition intensifies, leading to innovation and improved formulations aimed at enhancing efficacy and safety. As a result, the dengue vaccine market is witnessing robust growth, with projections indicating sustained expansion in market share and revenue for key players in the years to come.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies)
|
|
Country covered
|
U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Viatris Inc. (U.S.), Johnson & Johnson Services (U.S.), Inc., GSK plc. (U.K.), Perrigo Company PLC (Ireland), Baxter (U.S.), Fresenius Kabi USA (U.S.), Pfizer(USA), Hikma Pharmaceuticals Plc (U.S.), SUN PHARMACEUTICAL INDUSTRIES LTD (India), Teva Pharmaceuticals USA, Inc. (Israel), and Aurobindo Pharma (India) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
Global dengue treatment market is segmented into nine notable segments based on strains, type, severity, route of administration, mode of purchase, gender, age, end user, and distribution channel.
- Based on strains, the market is segmented into DENV-2, DENV-3, DENV-1, DENV-4, and others.
In 2024, DENV-2 segment of the strains type is expected to dominate the Global Dengue Treatment Market
In 2024, DENV-2 segment is expected to dominate the global dengue treatment market with 36.76% market share due to the high incidence rate of DENV2 virus.
- Based on type, the market is segmented into vaccines and acetaminophen.
In 2024, the vaccines segment of the type is expected to dominate the Global Dengue Treatment Market
In 2024, the vaccines segment is expected to dominate the global dengue treatment market with 47.02% market share due to the effectiveness of the dosage form in comparison to the orals.
- Based on severity, the market is segmented into mild to moderate dengue and severe dengue. In 2024, mild to moderate dengue segment is expected to dominate the global dengue treatment market with 61.85% market share
- Based on route of administration, the market is segmented into parenteral and oral. In 2024, parental segment is expected to dominate the global dengue treatment market with 83.41% market share
- Based on mode of purchase, the market is segmented into prescription and Over-the-Counter (OTC). In 2024, prescription segment is expected to dominate the global dengue treatment market with 83.81% market share
- Based on gender, the market is segmented into male and female. In 2024, male segment is expected to dominate the global dengue treatment market with 72.29% market share
- Based on age, the market is segmented into pediatric, adult, and geriatric. In 2024, adult segment is expected to dominate the global dengue treatment market with 59.12% market share
- Based on end user, the market is segmented into hospital, specialty clinics, home healthcare and others. In 2024, hospital segment is expected to dominate the global dengue treatment market with 58.96% market share
- Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. In 2024, retail pharmacies segment is expected to dominate the global dengue treatment market with 53.92% market share
Major Players
Data Bridge Market Research analyzes Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Viatris Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Inc., GSK plc. (U.K.) as the major players operating in the market.
Market Development
- In May 2024, Johnson & Johnson (JNJ) revealed its definitive agreement to acquire Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Numab therapeutics, in an all-cash transaction valued at around USD1.25 billion. This strategic acquisition is poised to bolster JNJ's growth trajectory by expanding its portfolio in the biopharmaceutical sector. By integrating YJT's innovative pipeline and expertise, JNJ aims to enhance its capabilities in developing novel therapies, ultimately strengthening its position as a leader in the healthcare industry
- In August 2023, according to the article by the FDA, DENGVAXIA, a tetravalent live vaccine manufactured by Sanofi Pasteur, Inc., is indicated for the prevention of dengue disease caused by serotypes 1, 2, 3, and 4 of the dengue viruses. Approved for individuals aged 6 through 16 years, it is specifically targeted at those residing in endemic areas who have a laboratory-confirmed previous dengue infection. This vaccine represents a significant advancement in combatting dengue fever, offering targeted protection against multiple serotypes of the virus, thereby potentially reducing the incidence rate of dengue infections in vulnerable populations
- In February 2024, according to the article by Takeda Pharmaceutical Company Limited., the company committed to producing up to 50 million doses annually of QDENGA, the Dengue Tetravalent Vaccine (Live, Attenuated), accelerating Takeda's goal of delivering 100 million doses per year by 2030. These multi-dose vials (MDVs) are designated to aid in government procurement for National Immunization Programs in endemic countries by 2030, facilitating broader access to dengue vaccination and contributing to global disease prevention efforts. Additionally, two live-attenuated dengue vaccines are in phase 3 developments which are, the TDV developed by Takeda and the LAV Delta 30 developed by NIH/Butantan Institute
- In July 2019, Hikma Pharmaceuticals Inc. and Civica Rx signed long-term agreement to minimize the future generic drug shortages in the US region this will help the company to expand their generics sales and to build a customer base which will increase the net revenue and sales
- In November 2019, Perrigo Company plc announced that their “Quitting is Better” therapy campaign has won a notable national award for the Best OTC Corporate Social Responsibility Campaign. The company won for innovation and strategic marketing by a panel of volunteer judges comprised of industry representatives that are members of the Consumer Healthcare Products Association (CHPA). This will increase the company profile in the global region
Regional Analysis
Geographically, the countries covered in the global dengue treatment market report are U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
Asia-Pacific is the dominant and fastest growing region in the Global Dengue Treatment Market
Asia-Pacific is expected to dominate the market due to its rising dengue incidence rate result in the demand for effective treatment and growth of medical insurance in emerging countries.
For more detailed information about the global dengue treatment market report, click here – https://www.databridgemarketresearch.com/ru/reports/global-dengue-treatment-market
